Dermapharm Holding SE: Strong Branded Pharmaceuticals Segment Fuels Organic Growth

Dermapharm Holding SE achieved solid organic growth in its branded pharmaceuticals sector, compensating for reduced vaccine production revenue. Unadjusted EBITDA rose 7.3% to EUR 147.0 million, with a margin improvement to 25.4%.

Consolidated revenue and adjusted EBITDA saw minor decreases year-on-year, largely due to weaker performance at Arkopharma Group in France. Despite this, the company remains confident, forecasting consolidated revenue of EUR 1,170–1,210 million and adjusted EBITDA of EUR 305–315 million for FY 2024.

Dermapharm also highlighted significant gains in the branded pharmaceuticals segment, with a 5.0% increase in revenue and a 14.5% rise in unadjusted EBITDA. Challenges in the 'Other healthcare products' segment were noted, but the Board of Management maintains a positive outlook for H2 2024.